GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pardes Biosciences Inc (NAS:PRDS) » Definitions » Earnings Power Value (EPV)

Pardes Biosciences (Pardes Biosciences) Earnings Power Value (EPV) : $2.54 (As of Jun23)


View and export this data going back to 2021. Start your Free Trial

What is Pardes Biosciences Earnings Power Value (EPV)?

As of Jun23, Pardes Biosciences's earnings power value is $2.54. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Pardes Biosciences Earnings Power Value (EPV) Historical Data

The historical data trend for Pardes Biosciences's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pardes Biosciences Earnings Power Value (EPV) Chart

Pardes Biosciences Annual Data
Trend Dec20 Dec21 Dec22
Earnings Power Value (EPV)
- - -

Pardes Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pardes Biosciences's Earnings Power Value (EPV)

For the Biotechnology subindustry, Pardes Biosciences's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pardes Biosciences's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Pardes Biosciences's Earnings Power Value (EPV) falls into.



Pardes Biosciences Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.


Pardes Biosciences  (NAS:PRDS) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Pardes Biosciences Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Pardes Biosciences's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pardes Biosciences (Pardes Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2173 Salk Avenue, Suite 250, PMB No. 052, Carlsbad, CA, USA, 92008
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Executives
Fs Development Holdings Ii, Llc 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Sean P. Brusky officer: Chief Commercial Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Thomas G Wiggans director, officer: Chief Executive Officer
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Pottage John C Jr director ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511
Alsup Laurie Smaldone director 190 WOOSAMONSA RD, PENNINGTON NJ 08534
Heidi Henson officer: Chief Financial Officer 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Brian Philippe Tinmouth officer: Chief Business & Strategy Ofcr 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Brian Kearney officer: Chief Development Officer C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Lee D Arnold officer: Chief Scientific Officer C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013
Uri A Lopatin director, officer: President and CEO C/O ASSEMBLY BIOSCIENCES, INC., 99 HUDSON STREET, 5TH FLOOR, NEW YORK NY 10013